Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

guidelines.recommendations.jpg

VA/DoD 2025 Obesity Guidelines

Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. Here is a review of the guidelines, including five key takeaways for rheumatologists.

Read Article
RheumNow Podcast square

Rheumatology Pay Up (9.25.2026)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Dick, Jack

Good Grief

When it rains it pours, but when it comes to grief, it’s like the rains that just won't let up.Just too many deaths this past month. All devastating, all my immediate sphere. All hard to fathom. How can something so inevitable be a recurring, unwelcome, unsolvable bad dream?

Read Article
Pss.renal.crisis.kidney

Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis

Prognostication is tenous in early scleroderma, especially in those with diffuse cutaneous systemic sclerosis (dcSSc). dcSSc has associated with substantial morbidity and disease-specific mortality.

Read Article
GCA.glossary.wordle

Steroid Delusions in Giant Cell Arteritis

A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.

Read Article
Advance growth

Endocrine Society - State of Obesity Science and Management

The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, the biology of which is being tested effectively by GLP-1/GIP receptor agonists. Is this precision-medicine? We await long-term safety data, while assessing the outcomes in rheumatic and musculoskeletal disorders.

Read Article
Nurse_0.jpg

Lifestyle and Incretin Therapy Advice for Rheumatologists

As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct implications for how we counsel obese patients we start or co-manage on these agents.

Read Article
RheumNow Podcast square

Early RA Referral Clinics Work (9.18.2026)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
HLA-B%2A2705.png

Review of HLA-B27

HLA-B27 remains the dominant genetic link to spondyloarthritis (SpA) across the age spectrum, but B27 related clinical expression diverges between children and adults. New mechanistic data on autoreactive T cells, HLA-B27 misfolding, and gut-joint trafficking point to new plausible, targetable pathways.

Read Article
infusion.biologic.jpg

Added IVIG is Effective in Myositis

A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagn

Read Article
×